STAT+: Allogene CEO David Chang stepping down

STAT PlusNewsletterThe Readout Allogene CEO David Chang stepping down Pfizer invests billions to buy Chinese drugs, WHO maps experimental response to Ebola outbreak, and other biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanMay 29, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hiya. In this week’s episode of “The Readout LOUD,” biotech vet Jeremy Levin talks about how scientific progress is outpacing the institutions that support it. Also, WHO experts are recommending the use of an antiviral and two monoclonal antibodies in the response to the Bundibugyo Ebola outbreak, and Allogene CEO David Chang is stepping down.Advertisement The need-to-know this morning Replimune Group said it had reached an agreement with the FDA to resubmit its experimental melanoma drug for approval, after the therapy was twice rejected by the agency. Albert Bourla loves China We are referring, of course, to the Pfizer CEO, who is once again putting billions of dollars of Pfizer cash on the table to buy drugs invented in China. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout June 1, 2026 STAT Plus: A turning point for pancreatic cancer patients Biotech June 1, 2026 STAT Plus: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug Advertisement Biotech May 31, 2026 STAT Plus: A standing ovation for RevMed, and caution for Akeso Pharma May 31, 2026 Ultra-low doses could bring costly cancer treatments to more patients in poorer countries Biotech May 31, 2026 STAT Plus: Practice-changing results reported for Revolution Medicines pancreatic cancer drug Subscriber Picks